How deficient are vitamin D deficient critically ill patients? by Lee, Paul
Vitamin D research has entered a renaissance in the past 
decade, with growing awareness of its pleiotropic actions 
beyond musculoskeletal health. Vitamin D deﬁ  ciency is 
now implicated in the pathogenesis of a wide range of 
conditions, including infection, vasculopathy, metabolic 
disorders and cancer, and the therapeutic potential of 
vitamin D is a topic of intense interest. In the current 
issue of Critical Care, Amrein and colleagues report the 
eﬃ     cacy and safety of a single dose of 540,000 units 
cholecalciferol (vitamin D3), given orally/enterally, to 
critically ill patients [1].
Vitamin D research in acute critical care is in its 
infancy, due to the traditional bias of vitamin D deﬁ  ciency 
being a chronic condition. Th  is belief has been over-
turned by recent studies associating vitamin D deﬁ  ciency 
with acute life-threatening hypocalcaemia, cardiac failure 
and increased mortality in critically ill patients [2,3]. 
Whether vitamin D replacement improves outcomes in 
critically ill patients is unknown.
Vitamin D replacement in critically ill patients is 
theoretically problematic. Oral and enteral formulations 
may be ineﬀ  ective due to malabsorptive processes arising 
from gastrointestinal oedema and inﬂ  ammation.  Th  e 
intra  muscular route is relatively contraindicated in 
patients with coagulopathy or in patients receiving 
anticoagulants. Intravenous supplementation up to 500 
units daily in parenteral feed, more than doubling the 
conventional regime, failed to correct deﬁ  ciency [4]. Th  e 
failure to achieve vitamin D suﬃ   ciency in early studies 
has indicated the need for an alternative regime, but the 
eﬃ     cacy of high-dose vitamin D supplementation in 
critically ill patients has only been reported recently [1,5].
Th  e deﬁ  nition of vitamin D suﬃ   ciency in the general 
population is a subject of ongoing debate. Th  e  proposed 
optimal vitamin D level ranges from 20 to >32 ng/ml. 
While the optimal level in critical illness is yet to be 
deﬁ  ned, applying these cut-oﬀ   points means a single dose 
of 540,000 units cholecalciferol, used in the current study 
[1], is capable of restoring vitamin D suﬃ   ciency  in 
critically ill patients as early as within 24 hours of 
administration (mean 25-hydroxyvitamin D (25(OH)D) 
>20  ng/ml) and certainly by 1  week (mean 25(OH)D 
>38 ng/ml). Th  ese  ﬁ  ndings are similar to those reported 
by another recent study demonstrating eﬃ   cacy  of 
120,000 units in divided doses [5].
Th  e increment of 25(OH)D in the current study 
(~22 ng/ml by day 3) stands in contrast to that reported 
in the general population. Th  e mean rise in 25(OH)D 
3  days after a similar single dose (300,000 to 
600,000 units) of cholecalciferol was two or three times 
higher (40 to 60 ng/ml) in community-dwelling indivi-
duals [6,7]. While baseline vitamin D status and obesity 
may determine response to vitamin D supple  ments [8], 
baseline 25(OH)D concen  trations were not markedly 
diﬀ  erent (13 to 15 ng/ml) and the reported mean body 
mass index was <30 kg/m2 in these studies.
Th  ese intriguing diﬀ   erences have shed light on the 
pathogenesis of vitamin D deﬁ  ciency in critical illness. 
Lesser increments in 25(OH)D concentration in critically 
ill patients, as observed in the current study, may relate to 
impairment in absorption, hydroxylation or vitamin D 
transport. Another hypothesis is an increase in tissue 
vita  min D requirement during critical illness, resulting in 
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dihydroxy  vitamin D on a tissue level [3]. Th  is is sup-
ported by the more severe degree of secondary hyper-
parathyroidism at baseline and the surge in 1,25-  di-
hydroxy  vitamin D concentration shortly after vitamin D 
replacement in the critically ill population.
Collectively these results suggest a higher replacement 
dosage may be required in critically ill patients compared 
to the general population, implying critically ill patients 
may be more deﬁ   cient than the measured serum 
25(OH)D concentrations indicate. Future studies should 
evaluate changes in vitamin D metabolites, their binding 
proteins and the parathyroid axis following diﬀ  erent 
dosing regimes, to determine how vitamin D metabolism, 
tissue requirement and renal handling of metabolites are 
aﬀ  ected during critical illness.
If critically ill patients are profoundly deﬁ  cient  in 
vitamin D due to increased tissue requirement for this 
pleiotropic hormone for immune defence and metabolic 
regulation, does vitamin D treatment improve outcome? 
Th  is is reminiscent of the growth hormone story, with 
similar enthusiasm over the potential beneﬁ  ts of growth 
hormone in critical illness a decade ago, which ended in 
disappointment when studies showed that high-dose 
growth hormone treatment increased mortality [9].
Is high-dose vitamin D supplementation safe in 
critically ill patients? Th  e current study revealed no 
occurrence of hypercalcaemia in any patients, as suppor-
ted by similar safety data in the general population. A 
recent randomised controlled trial surprisingly revealed 
an increased risk of falls and fractures in community-
dwelling women treated with a single dose of 500,000 
units oral cholecalciferol [10], thus raising safety con-
cerns surrounding high-dose supplementation, inde  pen-
dent of hypercalcaemia. Causes of this unexpected harm 
are unclear but could be related to stunning from the 
ultra high dose and protective upregulation of the 
enzyme 25-hydroxyvitamin D-24-hydroxylase, which 
catabolises 1,25-dihydroxy  vitamin D, thus paradoxically 
reducing its tissue level [11]. A more physiologic regime 
consisting of more frequent dosing of lesser amounts of 
vitamin D may be similarly eﬀ  ective and should be tested 
in critically ill patients.
Th  ere is currently tantalising circumstantial evidence 
supporting a therapeutic role for vitamin D in critical 
illness. An eﬀ  ective vitamin D dosing regime will set the 
stage for undertaking intervention studies to investigate 
the impact of vitamin D supplementation on outcomes in 
critical illness. We wait eagerly for vitamin D to declare 
its true identity: is it a novel pleiotropic saviour, or 
another bystander in critical illness?
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